SkyKick Releases Major Platform Upgrades with New Intelligent Cloud Backup Product, Revamped Security Manager, and Next-Generation Migration Suites
27.7.2023 15:00:00 EEST | Business Wire | Press release
SkyKick (https://www.skykick.com), a global leader in cloud automation and management solutions for information technology service providers (ITSPs), today announced major enhancements to its Cloud Management Platform. New products and updates deliver enhanced data protection capabilities and personalized security insights, enabling ITSPs to meet the growing demand for robust security solutions and conversations in the SMB market. This marks the biggest platform update in the company’s ten-year history.
In an era dominated by data and AI, security is a top concern for 88% of SMB customers. Despite overall IT budgets staying flat or even declining, 42% of SMB business owners are open to investing more in security and data protection solutions. SMB appetite for MSP security services continues to grow against the backdrop of increased Microsoft 365 adoption (now with an estimated 382 million commercial users worldwide) and the proliferation of sensitive data that is being created in the cloud. ITSPs are struggling to meet demand.
“As pioneers in Microsoft 365 cloud data protection and security, we closely monitor usage and adoption trends among customers and partners," said SkyKick Co-CEO Todd Schwartz. "We’re seeing that in order for ITSPs to turn customer appetite into a successful security and data protection business, they need better and more intelligent tools. Our new products make it easy for ITSPs to not only meet customer demand, but also build a successful security practice – one that is easy to sell and easy to manage."
SkyKick is announcing a reimagined Cloud Backup product, offering Intelligent Data Protection for Microsoft 365. Among the exciting new features is SmartInsights, a new capability that enhances customer engagements through insights on data growth and protection trends. Today, customers are proactively seeking to understand their data protection status. With SmartInsights, ITSPs can tap into this customer appetite and transform data protection into a valuable differentiator.
Beyond SmartInsights, the new Cloud Backup introduces a user-centric architecture that streamlines ease of use for ITSPs. Examples include a new Groups Management functionality, which scales onboarding and offboarding processes. Extending the comprehensive Microsoft 365 coverage, protection for Microsoft Planner data is now also included. Collectively, the new Cloud Backup reimagines data protection for the modern ITSP, reducing time to resolution and increasing customer satisfaction.
Additionally, SkyKick has revamped its Security Manager solution, which now has millions of SMB end-users under management since its debut in the fall of 2022.
“For partners to fully deliver on the customer promise, they need to go beyond data protection. We created Security Manager to help partners be more proactive on security and grow a stronger practice,” said SkyKick Co-CEO Evan Richman. “Today, SkyKick is announcing SecurityRadar, a key innovation within Security Manager, purpose-built to arm 100,000 Microsoft cloud partners with data-driven security insights they can use to drive proactive and personalized customer engagement.”
Beyond SecurityRadar, Security Manager is upgrading its proprietary Microsoft Partner Center Connector (PCI) with new sync technology that is 2X faster and more automated - further simplifying day-to-day customer management and Microsoft-mandated GDAP compliance.
Early market reaction to the new updates has been very positive.
“Security is a top priority for Kinetix and New Charter Technologies. We are excited about the new innovations in Security Manager, and SecurityRadar is a game-changer for us,” said Robert Herbaugh, Security and Strategy Specialist at a leading MSP. “By facilitating strong customer conversations on security, it is helping us drive increased customer value and revenue growth.”
SkyKick is also announcing the next major version of its industry-leading Migration Suites. Between a streamlined setup, a more performant sync technology, and a highly configurable new migration experience – SkyKick has reimagined the “easiest way to Microsoft 365” with even more ease, flexibility, and control for the modern ITSP.
ITSPs, as well as their customers, deserve the assurance of knowing that their technology itself is certified to be robust and enterprise-grade. Building on its numerous other certifications, the SkyKick platform and system is now certified for ISO 27001, ISO 27701 and Data Pro.
SkyKick Co-CEO Evan Richman noted, “Our fundamental vision remains to be the platform of choice for ITSPs building and growing a business around Microsoft 365. With the major enhancements that we are announcing now across Migrations, Backup, Security Manager, and Certifications, we are confident that SkyKick will help IT partners to stay ahead of challenges and deliver a truly differentiated value in the channel.”
About SkyKick
SkyKick is a global provider of cloud management software for IT Services Providers. The company is headquartered in Seattle, Wash., and has offices in Amsterdam, Sydney, and Tokyo. Its products are designed to help build successful cloud businesses by making it easy and efficient for IT providers to migrate, backup, manage and secure their customers in the cloud. Over 30,000 partners worldwide use SkyKick’s products to accelerate their cloud business, and the company has won numerous awards including being named a Microsoft Partner of the Year, 2023 IAMCP Partner of the Year, Red Herring Top 100 North America winner and one of the “100 Best Companies to Work For” in Washington State. For more information visit www.skykick.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727023626/en/
Contact information
Paul Forecki
Voxus PR for SkyKick
skykickpr@voxuspr.com
253.208.3615
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
